Loading clinical trials...

Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions | Clinical Trials | Clareo Health

RECRUITING

Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions

NCT06648317•Peking University Cancer Hospital & Institute

View on ClinicalTrials.gov

Summary

To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with lung lesions.

Detailed Description

To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with different lung lesions, such as inflammation and lung cancer.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. 18-75 years old, male or female;
•2. Heart function is normal;
•3. Normal heart function;
•4. Estimated survival ≥12 weeks;
•5. Good follow-up compliance;
•6. presence of at least one measurable target lesion according to RECIST1.1 criteria;
•7. Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting the test; Fertile men and women must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the test;
•8. Patients recommended by clinicians to undergo PET/CT examination for tumor diagnostic staging;
•9. The subject patients could fully understand and voluntarily participate in the experiment, and signed the informed consent.

Exclusion Criteria

•1. Serious abnormality of liver, kidney and blood;
•2. Pregnant patients;
•3. Pregnant and lactation women;
•3\) unable to lie flat for half an hour; 4) Refuse to join the clinical investigator; 5) Suffering from claustrophobia or other mental diseases; 6) Other conditions that researchers deem unsuitable for participating in the experiment.

Locations (1)

Peking University Cancer Hospital & Institute

Beijing, Beijing Municipality, China

Key Dates

Start Date

November 21, 2024

Primary Completion Date

March 1, 2025

Completion Date

December 1, 2025

Last Updated

November 25, 2024

Enrollment

ESTIMATED participants

Conditions

Lung Cancer, Non-Small CellLung Infection

Interventions

FDG-PET

OTHER

Contacts

Nan Li

CONTACT

+86-13693090647 rainbow6283@sina.com

Xin Zhou, MD

CONTACT

zhouxinbjmu@163.com

Engagement of Veterans With Lung Cancer

NCT07219251

Lung Cancer (NSCLC)Lung Adenocarcinoma+4 more

View study

RECRUITINGPHASE1/PHASE2

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

NCT06405230

Lung Cancer, Non-Small Cell

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 25, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions

Inclusion Criteria

Exclusion Criteria

Engagement of Veterans With Lung Cancer

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Shared Decision Making on Radiation Dose for Lung Malignancies

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer